medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2023, Number 4

<< Back Next >>

Medicina & Laboratorio 2023; 27 (4)

Neonatal hyperbilirubinemia and the role of the clinical laboratory in diagnosis

Guamán-Noboa JM, Yauli-Flores CF

Language: Spanish
References: 29
Page: 369-381
PDF size: 115.57 Kb.


ABSTRACT

Introduction. Hyperbilirubinemia is the seventh leading cause of neonatal death, it affects about 60% of term newborns and 80% of premature infants. The objective of this study is to evaluate the usefulness of currently available clinical laboratory tests for the diagnosis of neonatal hyperbilirubinemia and to summarize the most frequent risk factors in neonates for developing hyperbilirubinemia. Methodology. A systematic review of different investigations in the data bases of Elsevier, PubMed, The Cochrane Library, and relevant article guides, published between 2018 and 2023 in the English language were included. The documents were examined with the PRISMA methodology. Results. The systematic review evaluated 14 papers on the diagnosis and risk factors of neonatal hyperbilirubinemia. 64.28% of documents established a gestational age ‹37 weeks as a risk factor, followed by family history in 57.14%, suboptimal feeding (neonatal malnutrition) in 50%, and congenital anomalies in 42.85%. 50% of documents established visual evaluation as a useful method to determine the presence of neonatal hyperbilirubinemia, 85.71% recommend the measurement of total serum bilirubin as a diagnostic test, while transcutaneous bilirubin was recommended in 64.28%. Conclusion. The exact quantification of total serum bilirubin by the clinical laboratory is considered the gold standard for the diagnosis, follow-up, and control of neonatal hyperbilirubinemia. Although transcutaneous bilirubin measurement and visual evaluation can also be used to determine the presence of hyperbilirubinemia, it has been observed that the result of these tests is often inaccurate.


REFERENCES

  1. Anderson NB, Calkins KL. Neonatal indirecthyperbilirubinemia. Neoreviews 2020;21:e749-e760. https://doi.org/10.1542/neo.21-11-e749.

  2. Zhang M, Tang J, He Y, Li W, Chen Z, Xiong T,et al. Systematic review of global clinical practiceguidelines for neonatal hyperbilirubinemia.BMJ Open 2021;11:e040182. https://doi.org/10.1136/bmjopen-2020-040182.

  3. van der Geest BA, de Graaf JP, BertensLC, Poley MJ, Ista E, Kornelisse RF, et al.Screening and treatment to reduce severehyperbilirubinaemia in infants in primarycare (STARSHIP): a factorial stepped-wedgecluster randomised controlled trial protocol.BMJ Open 2019;9:e028270. https://doi.org/10.1136/bmjopen-2018-028270.

  4. Thomas DH, Warner JV, Jones GR, Chung JZ,Macey DJ, Screnci A, et al. Total bilirubin assaydifferences may cause inconsistent treatmentdecisions in neonatal hyperbilirubinaemia. ClinChem Lab Med 2022;60:1736-1744. https://doi.org/10.1515/cclm-2022-0749.

  5. Hulzebos CV, Vitek L, Coda-Zabetta CD,Dvořák A, Schenk P, van der Hagen EA, etal. Diagnostic methods for neonatal hyperbilirubinemia:benefits, limitations, requirements,and novel developments. Pediatr Res2021;90:277-283. https://doi.org/10.1038/s41390-021-01546-y.

  6. Castillo A, Grogan TR, Wegrzyn GH, Ly KV,Walker VP, Calkins KL. Umbilical cord bloodbilirubins, gestational age, and maternal racepredict neonatal hyperbilirubinemia. PLoS One2018;13:e0197888. https://doi.org/10.1371/journal.pone.0197888.

  7. Kemper AR, Newman TB, Slaughter JL,Maisels MJ, Watchko JF, Downs SM, et al.Clinical practice guideline revision: Managementof hyperbilirubinemia in the newborninfant 35 or more weeks of gestation. Pediatrics2022;150:e2022058859. https://doi.org/10.1542/peds.2022-058859.

  8. Okumura A, Ichimura S, Hayakawa M, Arai H,Maruo Y, Kusaka T, et al. Neonatal jaundice inpreterm infants with bilirubin encephalopathy.Neonatology 2021;118:301-309. https://doi.org/10.1159/000513785.

  9. Jara-Aguirre JC, Norgan AP, Cook WJ, KaronBS. Error simulation modeling to assess theeffects of bias and precision on bilirubin measurementsused to screen for neonatal hyperbilirubinemia.Clin Chem Lab Med 2021;59:1069-1075. https://doi.org/10.1515/cclm-2020-1640.

  10. Orhon A, Topal H, Hakan N, Ozer EA. Cordblood nucleated red blood cell level: is it apredictive marker for neonatal jaundice? JLab Med 2018;42:171-175. https://doi.org/doi:10.1515/labmed-2018-0065.

  11. Boulanger E, Cates EC, Darling L, Joyce-Smith D, Keen A, MacDonald T, et al. Clinicalpractice guideline 18. Management of hyperbilirubinemiain healthy term and late pretermneonates. Toronto, Canada: Association ofOntario Midwives; 2019. Acceso 15 de mayode 2023. Disponible en https://www.ontariomidwives.ca/sites/default/files/2019-11/CPGManagement-of-Hyperbilirubinemia-PUB.pdf.

  12. Khurshid F, Rao SP, Sauve C, Gupta S.Universal screening for hyperbilirubinemiain term healthy newborns at discharge:A systematic review and meta-analysis.J Glob Health 2022;12:12007. https://doi.org/10.7189/jogh.12.12007.

  13. Okwundu C, Bhutani VK, Smith J, EsterhuizenTM, Wiysonge C. Predischarge transcutaneousbilirubin screening reduces readmissionrate for hyperbilirubinaemia in diverse SouthAfrican newborns: A randomised controlledtrial. S Afr Med J 2020;110:249-254. https://doi.org/10.7196/SAMJ.2020.v110i3.14186.

  14. Chatur N, Castro M, Young-Tai KF. Macularrash, thrombocytopenia, and hyperbilirubinemiain a preterm infant. Case RepPediatr 2019;2019:4076740. https://doi.org/10.1155/2019/4076740.

  15. van der Geest BA, de Mol MJ, Barendse ISA,de Graaf JP, Bertens LC, Poley MJ, et al. Assessment,management, and incidence of neonataljaundice in healthy neonates cared for inprimary care: a prospective cohort study. SciRep 2022;12:14385. https://doi.org/10.1038/s41598-022-17933-2.

  16. Springer SC, Annibale DJ, Windle ML, ClarkDA, Rosenkrantz T, Itan O. Kernicterus. NewYork, USA: Medscape; 2020. Acceso 15 demayo de 2023. Disponible en https://emedicine.medscape.com/article/975276-print.

  17. Zhang L. Severe neonatal hyperbilirubinemiainduces temporal and occipital lobe seizures.PLoS One 2018;13:e0197113. https://doi.org/10.1371/journal.pone.0197113.

  18. Alkén J, Hĺkansson S, Ekéus C, Gustafson P,Norman M. Rates of extreme neonatal hyperbilirubinemiaand kernicterus in children andadherence to national guidelines for screening,diagnosis, and treatment in Sweden. JAMANetw Open 2019;2:e190858. https://doi.org/10.1001/jamanetworkopen.2019.0858.

  19. Thanomsingh P. Clinical predictive score ofpredischarge screening for severe hyperbilirubinemiain late preterm and term infants.Pediatr Neonatol 2020;61:378-384. https://doi.org/10.1016/j.pedneo.2020.02.003.

  20. Queensland Health. Queensland ClinicalGuidelines, Maternity and Neonatal ClinicalGuideline, Neonatal jaundice. GuidelineNo. MN22.7-V9-R27. Queensland, Australia:Queensland Health; 2022. Acceso 10 de mayode 2023. Disponible en https://www.health.qld.gov.au/__data/assets/pdf_file/0018/142038/gjaundice.pdf.

  21. Bahr TM, Henry E, Hulse W, Baer VL, PrchalJT, Bhutani VK, et al. Early hyperbilirubinemiain neonates with down syndrome. J Pediatr2020;219:140-145. https://doi.org/10.1016/j.jpeds.2019.12.039.

  22. Siu SL, Chan LW, Kwong AN. Clinical andbiochemical characteristics of infants with prolongedneonatal jaundice. Hong Kong Med J2018;24:270-276. https://doi.org/10.12809/hkmj176990.

  23. Hulzebos CV, Vitek L, Coda Zabetta CD,Dvořák A, Schenk P, van der Hagen EA, etal. Screening methods for neonatal hyperbilirubinemia:benefits, limitations, requirements,and novel developments. Pediatr Res2021;90:272-276. https://doi.org/10.1038/s41390-021-01543-1.

  24. Owerko D, Ryan K, Cabacungan E, Yan K,Saudek K. Neonatal hyperbilirubinemia: Assessingvariation in knowledge and practice.PLoS One 2023;18:e0282413. https://doi.org/10.1371/journal.pone.0282413.

  25. Okwundu CI, Saini SS. Noninvasive methodsfor bilirubin measurements in newborns: A report.Semin Perinatol 2021;45:151355. https://doi.org/10.1016/j.semperi.2020.151355.

  26. Greco C, Iskander IF, El Houchi SZ, RohsiswatmoR, Rundjan L, Ogala WN, et al.Diagnostic performance analysis of the pointof-care bilistick system in identifying severeneonatal hyperbilirubinemia by a multi-countryapproach. EClinicalMedicine 2018;1:14-20.https://doi.org/10.1016/j.eclinm.2018.06.003.

  27. Johnson SM, Vasu V, Marseille C, Hill C, JanvierL, Toussaint P, et al. Validation of transcutaneousbilirubinometry during phototherapyfor detection and monitoring of neonatal jaundicein a low-income setting. Paediatr Int ChildHealth 2020;40:25-29. https://doi.org/10.1080/20469047.2019.1598126.

  28. Slusher TM, Vreman HJ, Brearley AM, VaucherYE, Wong RJ, Stevenson DK, et al. Filteredsunlight versus intensive electric poweredphototherapy in moderate-to-severeneonatal hyperbilirubinaemia: a randomisedcontrolled non-inferiority trial. Lancet GlobHealth 2018;6:e1122-e1131. https://doi.org/10.1016/s2214-109x(18)30373-5.

  29. Ngashangva L, Bachu V, Goswami P. Developmentof new methods for determination of bilirubin.J Pharm Biomed Anal 2019;162:272-285.https://doi.org/10.1016/j.jpba.2018.09.034.




2020     |     www.medigraphic.com